Sugar replacement slows cancer growth
Researchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Epigenetic drugs can increase tumour malignancy
/in News/by Thomas GabrielczykResearchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Mittwoch: Epigenetic drugs can increase tumour malignancy
/in News/by Thomas GabrielczykResearchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Forbion leads 40m financing in Inflazome Ltd
/in News/by Thomas GabrielczykInflammosome inhibitor specialist Inflazome Ltd has raised 40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
Boehringer and Epizyme enter US$300m deal
/in News/by Thomas GabrielczykBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
/in News/by Thomas GabrielczykResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
/in News/by Thomas GabrielczykAstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum […]
Antibiotic resistance spreading across Europe
/in News/by Thomas GabrielczykAntimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report.
Liquid biopsy: size matters
/in News/by Thomas GabrielczykA new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA).
Themis postpones IPO
/in News/by Thomas GabrielczykOne week after Austrian vaccine and cancer immunotherapy specialist Bioscience announced the terms of its initial public offering (IPO) and listing on Euronext Amsterdam, the company has postponed its IPO.